Archive for the ‘china retractions’ Category
How is that possible? A spokesperson for Springer told us that they have reason to believe a third-party company may have helped prepare the papers for publication, and in the process might have spread the material around to multiple manuscripts.
The details of the cluster are a bit perplexing, so bear with us. Two of the papers — that were published only months apart — have already been retracted, as we reported in April. Now, two other papers have been retracted from Molecular Biology Reports — and both notices cite the previously retracted papers. The new notices also say that there’s reason to believe that the peer-review process was compromised.
All papers conclude that a certain polymorphism could signal a risk for coronary artery disease among Chinese people.
We’ll start with the retraction notice for “Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study,” which cites the two papers that were retracted previously:
A journal has retracted an abstract after discovering the author didn’t submit it — and also because it appears “highly similar” to a previous publication in Chinese.
The abstract was presented at the 2nd International Conference on Biomedicine and Pharmaceutics in 2014, and lists Qing Guo as the sole author, based Wuhan, China at the China University of Geosciences.
According to the retraction notice, published in the Journal of Investigative Medicine last December, the organizer of the conference discovered Guo hadn’t consented to publish the abstract — moreover, it appeared to overlap with another article in Chinese, written by different authors: Read the rest of this entry »
They’re now retracting the paper, from Molecular Medicine Reports, because it originally reported that higher concentrations of retinoic acid (RA) were more effective in curbing the proliferation of brain tumor cells. But it seems that the RA dose made less of a difference than they originally believed, according to the retraction notice:
According to the retraction notices issued by Chemosphere, Hong-Wei Luo incorrectly claimed to be affiliated with the Oak Ridge National Laboratory (ORNL) in Tennessee in one of his three affiliations. His other institutions listed on the papers include universities in Singapore and China.
However, an official from the Nanyang Technological University (NTU) in Singapore, told us the work in the now-retracted papers was not carried out at the NTU either.
PLOS ONE has retracted three papers after the first author admitted to submitting the manuscripts without co-authors’ consent, and an investigation suggested that two out of the three papers had received faked reviews.
Last August, the same author — Lishan Wang of the Shanghai Jiao Tong University — lost two more papers (one in Tumor Biology and the other in Gene), also after the peer review process was found to be compromised. All five papers — which share other authors in common — were originally published in 2013, and four list Wang as the first author. The retractions follow an investigation by Shanghai Jiao Tong University.
So it’s always interesting to come across a notice sui generis, such as one that appeared in July in OncoTargets and Therapy, a Dove title, about a new way to detect tumor markers.
According to the retraction notice:
The last author added the authors plan to republish the paper once they work things out.
The work for the paper — about cell death in the aftermath of a brain hemorrhage — was started in one lab at the Department of Neurology at the Affiliated Hospital of Nantong University, and completed in another.
That led to a dispute, reports the retraction notice, issued by Neurochemical Research:
Are some cases of research fraud fixable with a correction notice?
A chemistry journal thought so in 2014, when it issued a correction notice for a 2012 paper after the first author admitted to manipulating an image. After an investigation, the publisher agreed the manipulation was a “clear breach” of its ethical guidelines, but decided not to retract the paper since the overall conclusions remain valid.
The last author told us the first author had to repeat the experiments under supervision, and received a “serious warning.”
It’s an older notice, but one we thought interesting enough to cover now. Once you’ve read through the journal’s reasoning, tell us if you agree with the decision to correct (rather than retract) the paper in a poll at the bottom of this post.
Here’s the correction for “A novel route for preparing highly proton conductive membrane materials with metal-organic frameworks,” issued by Chemical Communications:
PLOS ONE has now retracted the paper, noting that they were tipped off to the problems by a reader who raised concerns about some of the figures. The notice states that the study’s first author, Zhenni Zhang, takes full responsibility.
The last author of the paper — Zongfang Li from the Xi’an Jiaotong University in China — told us Zhang was his PhD student who was close to completing her PhD, but has now been expelled.
A plastic surgery journal has retracted a paper after a researcher claimed it contained three figures without his permission.
According to Aesthetic Surgery Journal’s retraction notice (which is paywalled, tsk tsk), the figures were reproduced from a paper published in a Chinese journal without the original authors’ knowledge or permission: Read the rest of this entry »